Chemical 'Fingerprinting' and Identification of Unknowns in Counterfeit Artesunate Antimalarial Tablets from Southeast Asia by Liquid Chromatography/Time-of-flight Mass Spectrometry by Hall, Krystyn Alter
CHEMICAL ‘FINGERPRINTING’ AND IDENTIFICATION OF UNKNOWNS IN 
COUNTERFEIT ARTESUNATE ANTIMALARIAL TABLETS FROM SOUTHEAST ASIA 












A Thesis  
Presented to 










In Partial Fulfillment  
Of the Requirements for the Degree 










CHEMICAL ‘FINGERPRINTING’ AND IDENTIFICATION OF UNKNOWNS IN 
COUNTERFEIT ARTESUNATE ANTIMALARIAL TABLETS FROM SOUTHEAST ASIA 
























Facundo M. Fernandez, Advisor 
School of Chemistry and Biochemistry 
Georgia Institute of Technology 
 
Jiri Janata 
School of Chemistry and Biochemistry 
Georgia Institute of Technology 
 
Boris Mizaikoff 
School of Chemistry and Biochemistry 
Georgia Institute of Technology 
 
 





I dedicate this work to my husband, Matthew.  Without his constant 
love and support, it would not have been possible.  Matthew, thank you 
for everything.  I love you. 
Thank you also to my family and friends who have supported me 




































I am extremely grateful to my advisor, Facundo Fernandez for his 
guidance and knowledge throughout this process.  Additionally, there 
were many others who assisted in this work: Paul N Newton, Michael D. 
Green, David Pizzanelli, Mayfong Mayxay, Arjen Dondorp, Nicholas J 
White.  Additionally, I am grateful to my committee and to all others that 
assisted me during my time at Georgia Tech. 
I am grateful for the funding that was provided by a starter grant 
from the Society of Analytical Chemists of Pittsburgh to F.M.F. and by 
startup funds from Georgia Tech Research Corporation.  The collection of 
artesunate samples was funded by the Wellcome Trust of Great Britain as 
part of the Wellcome Trust-South East Asian Oxford Tropical Medicine 
Research Collaborations.  I am grateful to all who have assisted in the 









TABLE OF CONTENTS 
 
ACKNOWLEDGEMENTS………………………………………………………………iv 
LIST OF TABLES………………………………………………………………………….vi 
LIST OF FIGURES………………………………………………………………………..vii 
LIST OF ABBREVIATIONS……………………………………………………………...viii 
SUMMARY……………………………………………………………………………….ix 
CHAPTER 1: INTRODUCTION…………………………………………………………1 
CHAPTER 2: LITERATURE REVIEW…………………………………………………….4 
CHAPTER 3: EXPERIMENTAL…………………………………………………………..6 
 3.1 Standards and Solvents………………………………………………….6 
 3.2 Sample Collection and Preparation…………………………………..6 
3.3 Liquid Chromatography –Mass Spectrometry for Tablet 
“Chemical Fingerprinting”…………………………………………………...7 
3.4 Active Ingredient Quantification………………………………………9 
3.5 Data Processing and Analysis for Chemical Fingerprinting……..10 
 
CHAPTER 4: RESULTS………………………………………………………………….13 
 4.1 Artesunate Content of Antimalarial Drugs from SE Asia…………13 
 4.2 Identification of the “Wrong” Active Ingredients…………………19 
4.3 Characteristics of the Packaging of Fake Artesunate Tablets….23 
4.4 Multivariate Clustering of LC-MS Chemical Fingerprints…………26 
 
CHAPTER 5: CONCLUSIONS………………………………………………………...37 
CHAPTER 6: RECOMMENDATIONS………………………………………………...38 





LIST OF TABLES 
 
Table 1 Sample origin for a set of artesunate tablets  
which tested positive in field colorimetric tests.  
The concentration of artesunate was obtained 
as the average from two separate determinations 
based on the [M+NH4]+  ion signal at m/z=402 
and the [M+Na]+ ion signal at m/z=407. The 
expected artesunate content is 50 
mg/tablet………………………………………................................18 
 
Table 2 Sample origin and type of fake holograms found 
in a set of artesunate tablets which tested 
negative in field colorimetric tests. The classification 
of the fake holograms is detailed in the text.  
N/D=not detected……………………………………………….….20 
 
Table 3 Erythromycin content in selected fake artesunate 
tablets. Absolute quantification was carried out  
only for erythromycin A.  The approximate relative 
concentrations of other types of erythromycins are 
listed as the percent chromatographic peak area 














LIST OF FIGURES 
 
Figure 1 Structures of artemisinin and its derivatives……………………....3 
 
Figure 2 Typical positive ESI spectra of 4 µM artesunate 
solution in a 50:50 MeOH:water mixture infused at 
200 µl min-1 (1 minute acquisition)………………………………..14   
 
Figure 3 Signal to noise ratio for the artesunate 
chromatographic signal versus window width used 
in the generation of selected mass chromatograms…………16 
 
Figure 4 Total ion chromatogram for an erythromycin 
standard (top) and sample 12053 (bottom)……………………22   
 
Figure 5 Accurate-mass electrospray in-source CID 
spectra of erythromycin standard (top) and  
sample 12053 (bottom)…………………………………………..…23   
 
Figure 6 Genuine and fake holograms present in the 
artesunate tablets packaging…………………………………….25   
 
Figure 7 Chemical fingerprint plots of fake artesunate tablets………..27   
 
Figure 8 KNN dendogram of the unfolded LC-MS intensity  
matrices obtained from fake artesunate tablets……………...30   
 
Figure 9 Three dimensional representation of the LC-MS 
intensity matrix for fake artesunate sample 12052…………….31   
 
Figure S-1 Detail of hologram from genuine artesunate tablets 
from Guilin Pharmaceutical………………………………………..39 
 
Figure S-2 Detail of first generation (Type 2) fake hologram from 
  fake artesunate tablets……………………………………………..39 
 
Figure S-3 Detail of second generation (Type 3) fake hologram  
  from fake artesunate tablets………………………………………40 
 
Figure S-4 Detail of third generation (Type 4) fake hologram 
  from fake artesunate tablets………………………………………40 
 
 viii













u……………………………………………………………………...unified mass units 











The production and distribution of counterfeit drugs is a serious 
worldwide health problem. One recent example is the appearance of 
fake artesunate antimalarial tablets in Southeast Asia. Due to the 
malevolent circumstances in which these fakes are produced, concern 
over the presence of toxic tablet ingredients is very much a legitimate 
health issue. Therefore, quantification of the amount of active ingredient 
present in tablets marketed as artesunate, a drug used for the treatment 
of the multidrug-resistant Plasmodium falciparum malaria in Southeast Asia 
required liquid chromatography coupled to mass spectrometry (LC-MS). 
This quantification allows the classification of the tablets as genuine, sub-
therapeutic or fake and the validation of field results using colorimetric 
tests. During the LC-MS experiments, there were the observations that 
several of the samples contained a “wrong” active ingredient (AI).  This 
was identified via accurate mass measurements, chromatographic 
retention time and in-source collision-induced dissociation (CID)as 
erythromycin, a common antibiotic. Using multivariate unsupervised 
clustering algorithms, the LC-MS data was utilized for “chemically 
fingerprinting” the fake tablet samples and investigating the similarities 
between them. The results of this initial survey show a correlation between 
 x
sample origin, the different types of fake authentication holograms found 

























Counterfeit drugs, as defined by The World Health Organization 
(WHO), are those which are “deliberately and fraudulently mislabeled 
with respect to identity and/or source”.1 Drug counterfeiting can apply to 
both branded and generic products and counterfeit medicines may 
include products with the correct ingredients but with fake packaging, 
with the wrong ingredients, without active ingredients, or with insufficient 
active ingredient”.1  Public health is at an increasing risk because of an 
apparent growing global epidemic of the manufacture and trade of 
counterfeit pharmaceuticals.  For example, over 50,000 people were 
inoculated with fake meningitis vaccines in 1995 in Nigeria, possibly 
resulting in the deaths of 2,500 children.1  In Haiti, Nigeria and Bangladesh 
approximately 400 children have died after ingesting counterfeit  
paracetamol (acetaminophen) syrup that was made using ethylene 
glycol, a toxic industrial solvent.2-4  Because of multiple fake drugs, an 
estimated 192,000 people died in the People’s Republic of China in 2001.5  
It is believed that approximately 10% of all pharmaceutical products sold 
worldwide are counterfeits2,6, representing a $32 billion/year industry. 
However, only a minority of counterfeit drug incidents are reported to the 
appropriate enforcement agencies, and thus numbers of those affected 
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by counterfeit drugs are likely to be grossly underestimated.7, 8  It has been 
estimated that more than half of counterfeit drugs available worldwide 
contain no active ingredients or contain a different active ingredient than 
that stated on the labeling and that nearly 10% contain contaminants.8   
Since the late 1990s, counterfeit drugs that mimic drugs used for the 
treatment of potentially-fatal tropical diseases, such as malaria, have 
been detected in increasing numbers.  Malaria is a major health problem 
in many tropical countries, specifically in sub-Saharan Africa and 
Southeast Asia.9  Each year, between 300 and 500 million people in Asia 
and Africa contract Plasmodium falciparum malaria and 1.5 million 
people, mostly children, die.10  Until an effective vaccine is found,11, 12 the 
control of malaria still depends on the use of effective antimalarial drugs 
and bednets.  However, during the past three decades malaria control 
has been hampered by an increase in the prevalence of drug-resistant 
malaria parasites.11, 13  This is a particularly severe problem in SE Asia, 
where reduced sensitivity to other antimalarials such as chloroquine, 
sulphadoxine-pyrimethamine, halofantrine, mefloquine and quinine has 
been reported.14 
Artesunate, an artemisinin derivative (Figure 1), is now the recommended 
treatment in many countries where drug-resistant malaria parasites exist9 
and has become the target of an extremely sophisticated and prolific 
counterfeit drug trade.7  This includes the counterfeiting of both the 
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artesunate tablets and packaging, which, to the untrained eye, look 
extremely similar to the authentic product.7, 15, 16  Counterfeit artesunate 












R1, R2=O    Artemisinin 
R1=H, R2=OH   Dihydroartemisinin 
R1=H, R2=OCH3   Artemether 
R1=H, R2=OCH2CH3  Arteether 
R1=H, R2=OCH2C6H5CO2H Artelinic Acid 
R1=H, R2=OCOCH2CH2CO2H  Artesunic Acid  
Figure 1: Structures of artemisinin and its derivatives. 
 
 
Southeast Asia17 where they have probably resulted in the deaths of 
numerous patients who would have otherwise survived the malarial 
infection.18  In addition, counterfeit quinine and mefloquine tablets and 
artemether injections have been found in Asia.15  In a study conducted in 
1999-2000, 38% of all artesunate tablet blisterpacks bought in Cambodia, 
Laos, Burma, the Thailand/Burma border, and Vietnam contained no 
active ingredient. 17,19 In a subsequent follow-up study conducted in the 
same area, in 2001-2, 53% of artesunate blisterpacks were counterfeit, 





The chemical analysis of counterfeit drugs poses a challenging task 
in terms of sample throughput, dynamic range and identification of 
unknowns. Recently, Deisingh has reviewed the analytical methods used 
to investigate counterfeit drugs.20  These methods include Raman 
spectroscopy21, near infrared spectroscopy22-24, thin layer 
chromatography (TLC) 25, gas chromatography (GC)20, liquid 
chromatography (LC)26 and LC coupled to tandem MS (LC-MS/MS)6.   
In the particular case of the chemical analysis of counterfeit 
antimalarial samples, only colorimetric and bulk property tests have been 
used thus far.27  Green et al. have developed a colorimetric test based on 
the Fast Red TR dye28, 29 for detecting artemisinin derived compounds such 
as artemether, artesunate and dihydroartemisinin in tablets. This 
colorimetric method was used in the first two field studies to investigate 
the prevalence of counterfeit artesunate.17  During these studies the 
usefulness of visual ‘taxonomic’ cues in detecting counterfeit artesunate 
was also demonstrated: an observer, who was unaware of the 
colorimetric test results, examined the holograms, bar codes, printing, 
crimping, color, size, weight, consistency, and taste of the putative 
artesunate tablets and then classified them as genuine or fake.17  Visual 
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inspection of the tablets was in exact agreement with the colorimetric test 
only in the first survey17, but not in the second.19  The counterfeiters appear 
to have responded to this information by producing more sophisticated 
counterfeit holograms and packaging, making it very difficult to 
distinguish the counterfeit and genuine drugs.30, 31 
The objectives of this work were two-fold.  The first objective was to 
develop an LC-MS methodology suitable for evaluating the artesunate 
contents of a set of genuine and fake artesunate tablets collected in SE 
Asia and to validate the results obtained in the field by the rapid 
artesunate colorimetric test.  The second objective was to “chemically 
fingerprint” the confirmed fake artesunate samples in order to examine, 
via multivariate clustering techniques, the similarities and differences 
between them.  Even in the absence of the expected active ingredient, 
the abundance, molecular weight distribution and chromatographic 
retention time of the excipients and impurities present in counterfeit drugs 
constitutes a unique chemical fingerprint.32  To date, this seems to be one 
of the first reported attempts to systematically study the composition of a 
set of counterfeit drug samples collected over a vast geographical area.  
The methodology presented here should prove useful in investigating 







3.1 Standards and Solvents 
Artesunate (CAS # 88495-63-0) and erythromycin, (CAS # 114-07-8) 
were obtained from Apin Chemicals Ltd and Fluka Biochemica, 
respectively, and used without further purification. Artesunate standards 
were prepared in HPLC grade methanol (Sigma Aldrich, St. Louis, MO).  
Erythromycin standards were prepared in a 50/50 solution (v/v) of HPLC 
grade acetonitrile (Sigma Aldrich, St. Louis, MO) and pure water 
(Barnstead International, Dubuque, IA).  All standards and samples were 
filtered through a 0.45µm PTFE membrane filter (Pall Corporation, Ann 
Arbor, MI) before analysis.  Fresh standards were prepared on a daily basis 
from stock solutions that were stored at 4° C.   
 
3.2 Sample Collection and Preparation 
Counterfeit and genuine artesunate tablets were collected in a 
wide area of SE Asia encompassing the following countries: Laos, Burma 
(Myanmar), Vietnam, Cambodia, Hong Kong and Thailand.17, 23, 29 Prior to 
analysis, tablets were crushed with a mortar and pestle and thoroughly 
homogenized.  For artesunate quantification, approximately 5 mg of 
sample were suspended in 1 mL of methanol and extracted for 2 hours on 
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a rotary shaker.  For erythromycin quantification and tablet 
“fingerprinting,” approximately 100 mg of sample were suspended in 10 
mL of a 50/50 acetonitrile/water (v/v) mixture and extracted on a rotary 
shaker for 2 hours.  Following extraction, all samples were filtered through 
a 0.45µm PTFE membrane filter.  Tablet extracts were kept refrigerated (4° 
C) until analysis.  Prior to analysis, samples were diluted with methanol or 
50/50 acetonitrile/water (v/v) on a case-by-case basis. 
 
3.3 Liquid Chromatography –Mass Spectrometry for Tablet “Chemical 
Fingerprinting” 
 
LC was performed on an Agilent 1100 system equipped with a 
solvent degasser, a binary pump, a thermostated column compartment 
(held at 25ºC), an autosampler and a diode array detector. A 2.1mm ID, 
150mm long Zorbax Extend-C18 column (Agilent, Palo Alto, CA) equipped 
with a precolumn was used in all of the experiments.  The LC was 
operated at a flow rate of 200 µL min-1, with an injection volume of 20 µL.  
The binary pump used HPLC grade water with 0.01% acetonitrile as mobile 
phase A and acetonitrile as mobile phase B.  The LC gradient started at 
5% B and ramped to 45% B until 7 minutes, then increased to 100% B from 
7 to 8 minutes and held at 100% B until 12 minutes.  The system was set with 
a 4 minute post-run time to equilibrate the column to the original mobile 
phase composition. To ensure maximum reproducibility, all the organic 
extracts obtained from fake tablets where run on the same day and by 
 8
triplicate sequential injections and blank runs were inserted between 
sample runs to eliminate sample carryover. 
The Agilent 1100 LC system was coupled to an AccuTOF orthogonal 
extraction TOF MS (JEOL, Peabody, MA) via an orthogonal electrospray 
interface operating at 2kV.  Although in principle, negative-ion 
electrospray ionization would be the first choice for artesunate (due to its 
carboxylic side chain, Figure 1) positive-ion mode electrospray was used 
to ensure that other active ingredients not containing phenolic or 
carboxylic moieties (if present) could be simultaneously detected.  The 
mass spectrometer electrospray source ion optics settings were as follows: 
inlet orifice, 30 V; ring electrode, 8 V, first skimmer, 5 V; ion guide bias 
voltage, 26 V; ion guide RF amplitude, 2000 V.  The nebulizing gas flow 
rate, the desolvation gas flow rate, the needle chamber compartment 
temperature and the inlet orifice temperature were: 1.0 L min-1, 2.5 L min-1, 
250ºC and 80ºC, respectively.  The multi-channel plate detector was set to 
2500 V.  Data collection was performed with a FastFlight digital signal 
averager (ORTEC, Oak Ridge, TN) with a data sampling interval of 0.5 
nsec and a spectrum recording interval of 0.4 sec.  Accurate mass 
measurements were performed using a 1 µM solution of reserpine for mass 
drift compensation.  The average mass resolution observed was between 
6000 and 6800 (FWHM).  The NIST mass spectral library (version 2.0 a) and 
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SciFinder scholar (CAS, 2004) were used to search for unknown 
compounds. 
 
3.4 Active Ingredient Quantification 
All samples were analyzed in a blind fashion (i.e. without a priori 
knowledge of the results of the colorimetric test or the sample origin) to 
avoid any possible bias.  Artesunate was quantified using similar LC-MS 
settings as previously described but with the following differences:  HPLC 
grade water with 0.01% methanol was used as phase A and methanol as 
mobile phase B.  The LC solvent gradient started at 35% B for 3 minutes.  
From 3 minutes and until 18 minutes it was ramped to 100% B, where it was 
held until 30 minutes.  After this, it was ramped back down to 35% B using 
a 15-minute ramp.  The system was set with a 7.5 minute post-run time to 
equilibrate the column prior to the next run.  With this gradient, the 
retention time for artesunate was 18.1 ±0.4 min.  The settings of the TOF 
mass spectrometer ion source optics were as follows: inlet orifice, 20 V; 
ring electrode, 10 V, second skimmer, 2 V; ion guide bias voltage, 36 V; ion 
guide RF amplitude, 2000 V.   
Erythromycin was quantified using flow injection-MS.  A Vici 
Cheminert M6-liquid handling pump (Valco Instruments Co. Inc. Houston, 
TX) operated at 200 µL min-1 was connected to a manual 6-way HPLC 
injection valve equipped with a 20 µL loop (Valco). The mobile phase 
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consisted of 50% acetonitrile in water. The calibration curve for 
erythromycin was linear between 2 nM and 145 nM.  Mass selected 
chromatograms allowed the creation of external calibration curves for 
quantification purposes.  The area of the mass-selected chromatographic 
peaks was integrated using MassCenter software v.1.0 (JEOL).  
 
3.5 Data Processing and Analysis for Chemical Fingerprinting 
Time-resolved mass spectral data was exported from the AccuTOF 
instrument in JEOL-DX ASCII format using a custom-made 
chromatographic peak processing list.  Conventional peak processing lists 
only allow spectra corresponding to chromatographic retention times 
where peaks are detected to be exported. However, our multivariate 
clustering approach requires every LC-MS run to be exported as an 
intensity matrix consisting of a fixed number of rows (retention times) by a 
fixed number of columns (m/z values).  In order to export mass spectra at 
every retention time an artificial train of sample injection pulses (and thus 
detectable “chromatographic” peaks) was generated by intermittently 
pumping a 5 µM reserpine solution with the Vici Cheminert M6 pump.  This 
pump was software-controlled by a timing routine which alternated 
between 20 µL injections at a flow rate of 200 µL min-1 followed by a 10 s 
pause.  In this way, the MassCenter ‘spectrum processing wizard’ was 
forced to generate an entry in the chromatographic peak processing list 
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at repetitive times.  This processing list allowed the exportation of LC-MS 
data of fake artesunate tablets which resulted in 44 mass spectra, each 
averaged over a 16.36 s retention time interval.  
Triplicate runs of twenty three fake artesunate tablets were 
processed using Matlab v. 7.0 (The MathWorks, Natick, MA).  The routines 
included in the PLS Toolbox (Eigenvector Research, Inc., Manson, VA) 
were used for multivariate clustering.  All calculations were performed on 
a dual-processor Dell Optiplex PC with 1GB RAM (Dell, Round Rock, TX).  
The parameters for the construction of the matrices used for multivariate 
clustering in Matlab as follows: first was the creation of a 44 by 18,001-
element matrix for each sample run filled with zeroes. Then, this matrix was 
filled with the LC-MS intensity values obtained from the JEOL ASCII files, 
which were rounded to the nearest 0.1 u. These intensity matrices contain 
44 averaged chromatographic retention times and 18000 m/z values 
(from 200 to 2000 u every 0.1 u).  After the creation of the intensity 
matrices, the data for the triplicate runs for each sample was visually 
inspected to eliminate any possible outliers (none found) and then 
averaged into a single matrix per sample. The m/z values between 200-
340 u and 1200-2000 u for these averaged matrices were set to zero as 
they did not contain any significant information.  In order to further 
remove noisy variables, a signal threshold was applied to all the matrices 
by setting to zero any other matrix element whose intensity was lower than 
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1200 arbitrary units.  Average matrices were unfolded into a 
44x18,001=792,044 element vector which contained, in one row, all mass 
spectra ordered by increasing retention times.  The vectors of all 23 
samples were then combined into a single 23 by 792,044 matrix.  
Multivariate clustering was performed on this matrix using K-nearest 





















4.1 Artesunate Content of Antimalarial Drugs from SE Asia 
Prior to quantification by LC-MS, the electrospray response of 
standard artesunate solutions was characterized. Artesunate yielded 
complex positive-ion electrospray spectra even at low capillary-skimmer 
potential differences and low concentrations.  A representative 
electrospray spectrum of artesunate is shown in Figure 2.  Multiple adducts 
and fragments are observed.  The major adduct ions present were 
[M+NH4]+ (m/z=402), [M+Na]+ (m/z=407), [2M+NH4]+ (m/z=786), and 
[2M+Na]+ (m/z=791).  The [M+H]+ ion was not observed, regardless of the 
organic solvent used to prepare the standards.  The total ion intensity of 
the Na+ and NH4+ adduct ions decreased when more energetic 
desolvation conditions were used. For a 4 µM artesunate standard, the 
relative abundance of the [M+Na]+ adduct decreased by a factor of 103 
and the [M+NH4]+ adduct ion disappeared when the capillary-skimmer 
potential difference was increased from 20 V to 80 V.  Increased stability 
of the Na-adducts has also been observed for other drug compounds 
such as corticosteroids.34  The extent of dimer formation was also 
dependent on the skimmer-capillary voltage.  Upon an increase in 
capillary-skimmer potential difference from 20 V to 80 V, the dimer was 
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completely dissociated; increasing the abundance of the monomeric 
adducts and fragments.  Fragment ions were observed at declustering 
 






























Figure 2: Typical positive ESI spectra of 4 µM artesunate solution in a 50:50 
MeOH:water mixture infused at 200 µl min-1 (1 minute acquisition).  The capillary-
skimmer voltage difference was 20Vand the electrospray needle voltage was 
2000V.   
 
 
potential differences as low as 20 V (the minimum declustering potential 
needed to effectively transmit ions). The most abundant in-source CID 
fragment ions observed were produced by the loss of C4H6O4 (m/z=118) 
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from the [M+H]+ ion ([M-C4H6O4+H]+, m/z=267) which may explain the 
absence of the protonated adduct in the spectrum.  Dimer ions 
produced the [2M-C4H4O3+Na]+ and [2M-C4H4O3+NH4]+ fragments.  At 
capillary-skimmer potential differences of 80V or higher, other ions such as 
the [M-HCOOH+Na]+ fragment were also observed.  
After the positive electrospray response was characterized mass-
selected LC-MS chromatograms for artesunate standards at varying m/z 
window widths were obtained in order to maximize sensitivity and 
minimize interferences during artesunate determination.  To select the 
optimum m/z window, the signal-to-noise ratio (S/N) at varying window 
widths (m/z) for two different adduct ions were examined (Figure 3). As it 
can be seen in Figure 3 window widths lower than 0.06 for [M+Na]+ and 
0.1 u for [M+NH4]+ resulted in a decrease in the observed S/N due to the 
exclusion of a significant fraction of the mass spectral peak intensity in the 
mass selected chromatogram.  Both for [M+Na]+ and [M+NH4]+, S/N was 
maximum at a window width of 0.2 u after which it remained constant or 
even decreased due to the inclusion of noise.  A window width of 0.2 u 
was therefore used for all LC-MS artesunate quantification experiments. 
Dimer formation reduced the linear working range of the calibration 
curves. At artesunate concentrations higher than 9 µM, the slope for the 
[M+Na]+ and [M+NH4]+ calibration curves was no longer constant and a 




















Figure 3: Signal to noise ratio for the artesunate chromatographic signal versus 
window width used in the generation of selected mass chromatograms.  (A) 
[M+Na]+ signal of a 1.1 µM solution, (B) [M+NH4]+ signal of a 2.1 µM artesunate 
solution.  Signal-to-noise ratios were determined using a built-in function in the 




have observed a similar behavior for different artemisinins and 
demonstrated that the addition of ion-pairing alkylamines to the LC 
mobile phase dramatically reduces multimer formation and increases the 
dynamic linear range.35  We chose not to use such an additive, to prevent 
formation of ion pairs with unknown compounds which could complicate 
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the early detection of unexpected active ingredients.  Fleckenstein et al. 
have recently reported the use of the [M-C5H8O6+H]+ fragment (m/z=221 
u) for quantification of artesunate in human plasma.36  However, that 
particular fragment ion was not observed in our experiments, regardless of 
the declustering voltage used. In an attempt to increase the dynamic 
linear range and accommodate the wide range of artesunate 
concentrations found in our sample set, we investigated the use of the 
high-energy [M-HCOOH+Na]+ fragment ion for quantification purposes. 
However, we found that for this ion, the repeatability of triplicate injections 
of artesunate standards could be as poor as 25 % (RSD), whereas for the 
ammonium and sodium adducts it ranged from 2% to 8%. Therefore, both 
the Na+ and NH4+ ion adducts were used for quantitation purposes. 
 Table 1 shows the artesunate content in selected tablets collected 
in Vietnam, Myanmar (Burma), Laos and Cambodia.  This sample subset 
represents only those tablets in which artesunate was positively detected 
via colorimetric methods.  The expected amount of artesunate in these 
tablets is 50 mg/tablet.  The amount of artesunate in most of the collected 
tablets falls within a ±15% range of the expected value, thus validating the 
results of the artesunate colorimetric test.  Interestingly, one tablet 
collected in Siem Reap (Cambodia) showed an amount of artesunate (20 
mg/tablet) substantially lower than the accepted range, and thus it 
should be considered substandard. Substandard artesunate tablets pose 
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Table 1: Sample origin for a set of artesunate tablets which tested positive in field 
colorimetric tests. The concentration of artesunate was obtained as the average 
from two separate determinations based on the [M+NH4]+  ion signal at m/z=402 





Sample origin/ collection place Colorimetric 
Test Result 
Artesunate Content 
(mg/tablet) via  
LC-MS 
5 Mae La, Thai/Myanmar border + 54 ± 1  
18 Ho Chi Minh City, Vietnam + 51 ± 6 
31 Vietnam + 54 ± 5 
32 Mueang Feuang, Laos + 49 ± 6 
39 Myitkyina, Myanmar + 42 ± 12 
12064 Sekong, Laos + 62 ± 4 
12065 Sekong, Laos + 57 ± 3 
12068 Attepeu, Laos + 65 ± 14 
13008 Siem Reap, Cambodia + 21 ± 2 
13013 Ko Kong, Cambodia + 58 ± 3 
63001 Phnom Phenh, Cambodia + 56 ± 2 
10401/1 Pakse, Laos + 57 ± 4 
10401/2 Pakse, Laos + 50 ± 7 
 
 
a great danger to public health because they can create an 
environment that selects drug-resistant parasite strains.37  The colorimetric 
artesunate test is unable to distinguish between standard and 
substandard tablets, emphasizing the need for quantitative (or at least 
semi-quantitative) analysis methods.  Table 2 shows the artesunate 
quantitation results for tablets that tested negative by the Fast Red dye 
test.  Although all of these samples were labeled as being manufactured 
by Guilin Pharma (Guilin, Guangxi, People’s Republic of China) and had 
seemingly authentic holograms on their packaging, they did not contain 
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artesunate in detectable amounts (less than 1 µg).  Overall, 64 % of all the 
artesunate samples did not contain the expected active ingredient, 
confirming previous findings by Rozendaal18, Newton et al. 17, 31 and 
Dondorp et al.19 and the most recent findings by de Veij et al.38 which 
indicated the widespread distribution of these fakes in mainland SE Asia.  
 
4.2 Identification of the “Wrong” Active Ingredients 
During artesunate quantitation, it was noted that several fake 
artesunate tablets described in Table 2 showed intense chromatographic 
signals with m/z values that could not be assigned to any artesunate 
adducts or fragments.  Samples 12050, 12052, 12053, 12054, 12057, 12060, 
12061 and 12062 (see Table 2), presented similar peaks in the 700-750 m/z 
range, but with different intensities.  This finding suggested that 
unexpected active ingredients were present in these fake artesunate 
samples.  The presence of wrong AIs in counterfeit antimalarials is not 
uncommon.  Some of the early counterfeit artesunate (collected in or 
before 1999) contained chloroquine which may have been added to 
give the counterfeits a bitter taste, as there is a tradition in SE Asia that 
antimalarials should be bitter.39  However, chloroquine has very low 
antimalarial efficacy throughout mainland SE Asia. 
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Table 2: Sample origin and type of fake holograms found in a set of artesunate 
tablets which tested negative in field colorimetric tests. The classification of the 














13 Myitkyina, Myanmar 1  - N/D 
980201 Ho Chi Minh City, Vietnam 1  
 
- N/D 
29 Ho Chi Minh City, Vietnam 2 - N/D 
97 Ho Chi Minh City, Vietnam 2 - N/D 
12050 Pakse, Laos 8 - N/D 
12051 Pakse, Laos 3 - N/D 
12052 Pakse, Laos 12 - N/D 
12053 Pakse, Laos 13 - N/D 
12054 Pakse, Laos 5 - N/D 
12055 Pakse, Laos 3 - N/D 
12056 Pakse, Laos 4 - N/D 
12057 Pakse, Laos 8 - N/D 
12058 Pakse, Laos 8 - N/D 
12060 Salavan Laos 8 - N/D 
12061 Salavan Laos 5 - N/D 
12062 Salavan Laos 12 - N/D 
12063 Salavan Laos 3 - N/D 
12067 Attepeu, Laos 3 - N/D 
12070 Paksong, Laos 4 - N/D 
12071 Paksong, Laos 3 - N/D 
13007 Siem Reap, Cambodia Yet to be 
classified 
- N/D 
13011/1 Anlong Veng, Cambodia 3 - N/D 
13011/2 Anlong Veng, Cambodia 3 - N/D 
 
 
Sample 12053 was chosen to further investigate the most prominent 
spectral peak in the 700-750 u region because of its lower intensity which 
made it more prone to accurate mass measurements.  The monoisotopic 
measured mass of the most intense peak was 734.4 u.  In a first approach, 
we assumed that this signal corresponded to the [M+H]+adduct ion.  
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Accurate mass analysis was then performed on sample 12053 extract 
using reserpine (m/z=609.2812 u) for mass scale drift correction purposes, 
yielding an exact mass value of 734.4703 u.  The closest match (-0.20 
ppm) to this value was found for an elemental composition of C38H64N5O9. 
However, an electronic search revealed no common pharmaceuticals 
with this composition.  The following candidate elemental composition 
was C37H68NO13 with a mass difference of 1.62 ppm and a theoretical 
mass equal to 734.4691 u.  A search within the NIST mass spectral 
database of this composition returned two matches, only one being an 
easily-obtained chemical compound. This compound was the common 
antibiotic erythromycin. 
Because of the severity of this finding, further confirmation of our 
accurate mass results was obtained by additional experiments.  Figure 4 
shows total ion chromatograms for both an erythromycin standard and 
sample 12053 showing matching retention times of 13.38 and 13.54 
minutes, respectively.  Figure 5 shows accurate-mass in-source CID 
spectra of both the standard and sample obtained in LC-MS function 
switching mode.  The most intense fragment at m/z=576 observed for the 
erythromycin standard corresponds to the ion with elemental composition 
of C29H54NO10 due to the loss of the cladinose sugar40 (C8H14NO3, 
m/z=158). A similar fragment ion was observed for sample 12053.  The 
relative abundance of the [M+H]+ isotopic peaks was also examined  
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RT=13.379
 
Figure 4: Total ion chromatogram for an erythromycin standard (top) and sample 
12053 (bottom).  The peak at retention time (RT) =13 minutes corresponds to the 
[M+H]+ erythromycin  ion.  The signals observed after 18 minutes correspond to 
the sum of intensities of solvent cluster ions and solvent impurities.  See 
Experimental for LC gradient settings.  
 
 
which, were100/40.6/13.2/3.1 for sample 12053 and 100/41.7/11.1/2.2 for 
the standard, further confirming our finding.  Follow-up experiments 
demonstrated that out of the twenty three tablets containing no 
artesunate (Table 2), nine tablets contained erythromycin. 
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Figure 5: Accurate-mass electrospray in-source CID spectra of erythromycin 
standard (top) and sample 12053 (bottom).  Capillary-skimmer voltage 
difference was 60V.  The peaks at m/z 576 and m/z=558 correspond to the 
C29H52NO9 and C29H54NO10, fragment ions. 
 
 
4.3 Characteristics of the Packaging of Fake Artesunate Tablets 
To this date, we have found at least thirteen different types of 
counterfeit artesunate tablet samples, based on the packaging 
appearance and holograms.17, 19, 31, 41  In this survey, we included samples 
belonging to most of these types.  It is outside of the scope of this article to 
describe in detail each type of fake hologram that we have found so far, 
and only a brief description is given here and in Appendix A.  
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The genuine artesunate hologram from Guilin Pharma (Figure 6A) is 
a 14 mm diameter self-adhesive label made in the People’s Republic of 
China.  This hologram was developed by Guilin Pharma as a security 
device in response to the first type (Type 1, see Table 2) of counterfeit 
artesunate that circulated without a hologram attached.41  The most 
interesting feature of the genuine hologram is that the outer ring is 
comprised of small grating segments (see Figure S-1).  The “Type 2” fake 
hologram (Figure 6B) affixed to counterfeit artesunate is made from 
diffractive “rainbow” foil, commonly used on counterfeit products, and is 
not a hologram; just a sticker (see Appendix: Figure S-2 for more details).  
As diffractive rainbow foil is widely sold as a decorative material, it is 
relatively simple to use this foil for manufacturing copies of the genuine 
holograms.  Fake hologram Types 8, 12 and 13 (Table 2) are foil stickers 
similar to Type 2, but Type 8 and 12 have a different mountain outlines and 
Type 13 is a sticker without any discernable pattern.  Type 5 is also a sticker 
in which the mountain outline, waves and circular surrounds are 
comprised of thousands of small dots.  The Type 3 fake holograms (Figure 
6C) attached to counterfeit “artesunate” is a simple 2D origination where 
the image is comprised of two exposures of diffractive color, one of which 
is much brighter than the other (Figure S-3).  The Type 4 fake hologram 
(Figure 6D) is very similar in appearance to the genuine hologram, despite  
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being manufactured using different techniques. In this case,  the 
hologram is comprised by a clean, 2D image in two contrasting colors, 







Figure 6: Genuine and fake holograms present in the artesunate tablets 
packaging. (A) Genuine artesunate hologram (Guilin Pharmaceuticals), (B) Type 






4.4 Multivariate Clustering of LC-MS Chemical Fingerprints 
In order to investigate the correlation between a samples origin, the 
presence of wrong active ingredients and the type of fake holograms 
observed in the packaging, multivariate clustering was performed on the 
LC-MS intensity matrices. First, the data in these matrices were visually 
inspected.  Figure 7 shows contour plots for all averaged intensity matrices 
obtained for the fake artesunate tablets included in this study.  Several 
similarities between samples can be readily found by visual inspection. 
Samples 12050, 12052, 12054, 12057, 12060, 12061 and 12062 show similar 
fingerprints; all eight of them are characterized by two distinct features. 
First, these samples present a polymeric species eluting at 2.1 min, 
characterized by peaks with a 171 u  spacing.  The second common 
characteristic of these samples is, as mentioned before, the presence of 
erythromycin.  When these samples were analyzed via Raman 
spectroscopy, it was determined that these samples also contain calcite 
(CaCO3) and that several of them, samples 12060, 12061, and 12062 also 
contain paracetamol.38  
Samples 980201 and 29 from Vietnam and 13007 from Cambodia, 
present fairly uninformative chemical signatures which could be 
considered compatible with the absence of any active ingredients and/ 
or the presence of inorganic excipients not extracted during the sample 






















Figure 7: Chemical fingerprint plots of fake artesunate tablets.  Sample code is 
indicated above each plot.  Each tablet’s data is the average of three LC-MS 
runs.  The x-axis represents m/z values and the y-axis represents the spectrum 
number collected at increasing chromatographic retention times.  These plots 
are a bidimensional representation of an LC-MS intensity matrix with MS mass-
to-charge values as columns, and spectrum number as rows.  Larger red dots 
denote the most intense signals whereas black small dots represent the 
weakest ones.  Signals with intermediate intensity were coded according to 
the following color scale: yellow>green>cyan>blue. 
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formulations is CaCO3.42  Indeed, when dilute acid was added to these 
samples, effervescence was observed.  The presence of CaCO3 was also 
validated via Raman spectroscopy.38 
The signal pattern observed in the chemical signatures for samples 
13011/1 and 13011/2 from Along Veng in Cambodia are very similar. 
These tablets come from two different, but physically identical blister 
packs, bought at the same time from the same shop. The lack of 
refrigerated storage of the samples in shops and pharmacies in the 
seasonally high ambient temperatures in SE Asia (up to 400C) may be the 
cause of the small differences between the samples’ fingerprints.  These 
samples show a similar polymeric peak eluting at 2 min, with a 162 u 
spacing, consistent with small  monomeric units of hexose, probably 
derived from partially-extracted low molecular starch-derived compounds 
(starch is a common filler for pharmaceutical tablets).42 
Following visual inspection of the data, unsupervised multivariate 
pattern recognition was performed on the LC-MS intensity matrices as 
described in Chapter 3.5.  Figure 8a presents the KNN dendrogram for the 
unfolded LC-MS data of counterfeit artesunate tablets extracts.  The first 
salient feature of this figure is that samples 12054, 12061, 12057, 12052, 
12050, 12062, and 12060, are clustered towards the top portion of the, 
dendrogram in a nested fashion. All these samples were collected in Laos 
and presented intense erythromycin signals and rainbow foil stickers(not 
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fake holograms).  Closer inspection of this sample subset (see for example 
sample 12052 in Figure 9) revealed several additional peaks in the 
erythromycin region.  Accurate mass measurements were performed on 
all these peaks, and the following chemical compounds were identified: 
erythromycin B (theoretical m/z=718.4714 u, observed m/z=718.4742 u); 
erythromycin C (theoretical m/z=720.4534 u, observed m/z=720.4547); 
erythromycin E (theoretical m/z=748.4483 u, observed m/z=748.4503 u); 
erythromycin F (theoretical m/z=750.4640 u, observed m/z=750.4633 u), 
and anhydroerythromycin (theoretical m/z=716.4585 u, observed 
m/z=716.4576 u).  Only erythromycin A was detected in sample 12053. 
Erythromycin formulations generally contain more than one type of 
erythromycin, with erythromycin A being the most abundant and 
generally referred to only as erythromycin.43  To further explain the 
clustering of the erythromycin-containing samples in the KNN 
dendrogram, we quantified erythromycin A via flow injection MS (Table 3).  
Fake “artesunate” tablets contained a total amount of erythromycins that 
ranged from 20 to 190 mg/tablet and thus, these samples could have 
significant therapeutic activity for sensitive bacterial infections, but no 
activity in malaria infections.  The order of the erythromycin-containing 
samples in the dendogram followed their erythromycin content, except 
for sample 12054, which was placed at the top of this diagram and 
contained 27 mg erythromycin-A/g tablet. This indicates that the absolute  
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Figure 8: KNN dendogram of the unfolded LC-MS intensity matrices obtained 
from fake artesunate tablets.  For a given pair of samples a small difference in 











Figure 9:  Three dimensional representation of the LC-MS intensity matrix for fake 
artesunate sample 12052 showing a detail of the region containing different. 
Peak labels describe retention time (min), m/z, relative intensity, and absolute 
intensity respectively.   Intense signals are observed for the following 
erythromycin components: C at m/z = 720.5, A at m/z = 734.5, E at m/z = 748.5 
and F at m/z = 750.5.  The signals for anhydroerythromycin A at m/z = 716 m/z, 
and erythromycin B at m/z = 718 were not labeled for clarity.  A threshold of 3% 
relative intensity was used to filter out background noise. 
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amount of erythromycin A was not the only variable determining the 
clustering of the samples.  The different patterns of detected 
erythromycins seem to also influence the grouping into different sub-
clusters. Table 3 lists the relative percent of other erythromycins in these 
samples expressed as % area. 
 
Table 3: Erythromycin content in selected fake artesunate tablets.  Absolute 
quantification was carried out only for erythromycin A.  The approximate relative 
concentrations of other types of erythromycins are listed as the percent 
chromatographic peak area relative to the sum of the areas of all erythromycin-
related compounds. 
 















































12054 27 ± 4 44.2 3.9 2.4 2.7 2.4 44.5 
12061 191 ± 7 46.5 8.5 35.8 3.9 0 5.3 
12057 58 ± 1 47.0 5.0 9.6 3.1 22.6 12.6 
12052 57 ± 5 57.4 2.9 2.5 8.5 17.1 11.6 
12050 50 ± 1 54.1 0.5 17.2 3.9 22.8 1.5 
12062 20 ± 5 80.6 0.8 11.1 4.5 0 3.0 
12060 <1 89.6 1.6 3.2 1.6 3.5 0.5 
12053 <1 100 0 0 0 0 0 
 
Some interesting observations can be derived if the sample 
clustering in the KNN dendrogram is examined together with the 
erythromycin A content, the pattern of erythromycins, the geographical 
origin and the type of fake hologram present in the packaging.  For 
example, samples 12054 and 12061 showed the same type of rainbow foil 
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sticker (Type 5) and they were collected in different (but nearby) cities 
(Pakse and Salavan, Laos). These samples were placed in separate 
branches in adjacent positions at the top of the dendogram, indicating 
that although they may be related; there are significant differences 
between them. Both samples contained erythromycin A, but in different 
amounts (27 and 191 mg/g respectively), and different proportions of 
erythromycin C and anhydroerythomycin A (a hydrolysis product of 
erythromycin A), which explains the different placement in the 
dendogram. These samples both also contain CaCO3 indicated via 
Raman spectroscopy analysis.  Although one can only speculate at this 
point, these observations might indicate that these two samples stem from 
separate batches that originated in a common production source at 
early stages of the counterfeiting operation, where the sophistication of 
the fake holograms was still low. 
Samples 12057, 12052 and 12050 are clustered as a sub-family of 
counterfeits which were all obtained in Pakse (Laos) and present similar 
rainbow foil stickers in their packaging (Types 8 and 12). These samples are 
different than samples 12054 and 12061, in that they all contain 
approximately 50 mg/g erythromycin A; however, they are the same in 
that they all contain CaCO3.  Samples 12052 and 12050 are further 
clustered into another subgroup, not far from sample 12057 due to their 
higher relative percentage of erythromycin A.  
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Samples 12062 and 12060 were both collected in Salavan (Laos) 
and presented similar rainbow foil stickers (Type 12 and 8). Their 
erythromycin fingerprint is similar (between 80 and 90% or erythromycin A) 
but they differ in their absolute erythromycin content.  However, they are 
similar in that they both contain paracetamol.  Sample 12058 (also 
presenting a Type 8 fake hologram) from Pakse, (Laos) does not contain 
erythromycin, and seems to be a class of its own, serving as a “boundary” 
between the Laos samples containing erythromycins with rainbow foil 
stickers and the remaining samples, all of them without erythromycins and 
presenting more elaborate packaging.  Sample 12058 contained the 
signature for starch, and two medium intensity peaks separated by 304 
mass units, previously not found in any other samples. 
The analysis of the similarities among samples without erythromycins 
(13 to 97) reveals a few more interesting trends (Figure 8b). Sample 13, 
collected in Myanmar seems to be a class on its own, with no fake 
holograms or stickers present in the packaging. This sample, collected in 
Myitkyina (Myanmar) is the most isolated, from the rest of the samples 
from a geographical point of view.  According to Raman, this sample also 
contains a starch compund.  Sample 980201, collected in Ho Chi Minh 
City, presented no fake holograms and a very simple fingerprint which 
partially resembled the fingerprint from a second Vietnam sample, 29, 
presenting a Type 2 rainbow foil sticker. These two samples were found to 
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contain mostly CaCO3 and might have been produced by the same 
manufacturing source, which added a fake rainbow foil sticker to its 
“product” in response to increased safety measures put in practice by the 
genuine manufacturers. 
Very interestingly, samples with fake holograms Type 3 and 4 are 
grouped together, and were all collected either in Laos or neighboring 
Cambodia. Samples 12071 and 12063 seem to be almost identical from 
the chemical point of view, with matching fingerprints, and placed 
together in the dendogram. Their packaging contained Type 3 holograms 
in both cases, but were collected in different and fairly distant cities (one 
in northern Laos and one in southern Laos), a clear sign of a common 
production or distribution source. Both samples were found to contain 
starch and a fairly concentrated component presenting mass peaks at 
438.3 u and 493.3 u, which could not be positively identified.  Sample 
12070, also collected in northern Laos, was chemically similar to 12071 and 
12063, but presented the most sophisticated type of hologram (type 4), 
pointing that this sample might belong to a more recent batch. Samples 
12051, 12055, 12056 and 13011 were collected in Pakse (Laos) and in the 
town of Anlong Veng in Cambodia (150 miles away) and appear to all be 
chemically related.  All but 13011 contain a starch component.  Sample 
12056 presented a realistic Type 4 fake hologram, similar to the one found 
in sample 12070.  The degree of similarity between samples with Type 3 
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and Type 4 fake holograms was much higher, if compared with the 

























This preliminary survey using LC-MS confirms the large prevalence of 
fake artesunate tablets with no detectable amount of active ingredient 
and reveals the presence of samples which contain subtherapeutic levels 
of artesunate.  One of the most severe findings is that several “wrong” 
active ingredients were detected in the fakes. Multivariate clustering of 
the LC-MS chemical fingerprints allowed an in-depth investigation of the 
similarities between the samples  for which it was observed that a 
correlation between sample origin, chemical composition and packaging 
exists, thus indicating that these “fakes” are the product of an organized 
international operation which has been flooding the market with fake 













Clearly, the analysis of more samples by the approach presented 
here or a similar one would be beneficial. The main limitation of the 
present LC-MS methodology is its low sample throughput. For this reason, it 
is necessary for the development of an additional analytical method. 
Recently, two innovative MS-based high-throughput methods for the 
analysis of real samples, including pharmaceuticals, in open air have 
been reported.  One of these described by Cooks et al. is DESI (Desorption 
Electrospray Ionization), which will increase the number of samples that 
can be analyzed in a time period of seconds or less.44  Later, Cody et al. 
reported an atmospheric-pressure Penning ionization technique marketed 
under the name of  DART® (Direct Analysis in Real Time).30It is expected 
that a DESI-based method will also be able to generate meaningful 
chemical fingerprints suitable to be examined via multivariate techniques. 
  It is also necessary to analyze a second sample set containing 
more than one hundred fake artesunate samples, to produce more 
densely populated clusters, which could lead to a better understanding 








            
     Main image detail, 2D artwork masks            Section of Kinetic Ring Feature             Kinetic Ring Grating Section (at X200) 
 




The central image is made in the “2D-3D” style (generated from flat 
graphic line artwork) but with some variations from the traditional 2D-3D 
method.  The image is only “2D” on the surface level, with no depth in the 
image.  At 60x magnification the areas of grating section that have been 
exposed around the ring can be seen.  At 200x magnification these 
sections can be seen to be doubly exposed in some areas.  This is a very 




               Main image detail, ragged lines            Section of Outer Ring Feature                   Outer Ring (detail) at X200  
Figure S-2: Detail of first generation (Type 2) fake hologram from fake artesunate 
tablets. 
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The fake ‘hologram’  affixed to Type 2 counterfeit artesunate is made 
from diffractive “rainbow” foil.  Rainbow foil is usually over-printed with ink, 
or hot-stamped, to create an image that simulates a true hologram.  The 
rainbow foil has been deep etched so as to remove selected areas of the 
surface and form an image.   
 
     
Main image (detail) Chinese characters           Section of Outer Ring Feature                      Outer Ring (detail) at X200  
Figure S-3: Detail of second generation (Type 3) fake hologram from fake 
artesunate tablets. 
 
The fake hologram attached to Type 3 counterfeit ‘artesunate’ is a simple 
2D origination where the image is comprised of two exposures of 
diffractive color, one of which is much brighter than the other.  The main 
exposure lights up the mountains and 50% of the sections in the outer ring 
of the image.  This ring feature is not kinetic as in the genuine hologram 




     
       Main image (detail) Chinese characters          Section of Outer Ring Feature                    Outer Ring (detail) at X200  
Figure S-4: Detail of third generation (Type 4) fake hologram from fake 
artesunate tablets. 
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The fake holograms on the Type 4 ‘artesunate’ counterfeits are very similar 
in appearance to the genuine hologram, despite using different 
techniques.  The central image is a bright, clean, 2D image in two 
contrasting colors.  Unlike the genuine hologram, both diffractive colors 
are made using the McGrew method45 for making rainbow colors, (with 
diffused object beams, rather than un-diffused gratings) and thus have 
higher brightness than the genuine hologram.  As in the genuine 
hologram, the kinetic feature of the outer ring is not composed of dots 
made by a dot-matrix machine, but it is formed of sections in three 
different diffractive colors (two of which are the same colors as the main 
image). These colors are repeated to provide an apparent animation 
when the hologram is tilted vertically, rather than right-to-left as in the 
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